Efficacy and Antimicrobial Activity of Platelet Rich Plasma (PRP) in Acne Vulgaris
1 other identifier
interventional
50
0 countries
N/A
Brief Summary
Efficacy and Antimicrobial activity of Platelet Rich Plasma (PRP) in Acne Vulgaris : A randomized controlled trial
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started Jan 2020
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 28, 2019
CompletedFirst Posted
Study publicly available on registry
March 1, 2019
CompletedStudy Start
First participant enrolled
January 10, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 10, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 10, 2022
CompletedMarch 5, 2019
February 1, 2019
1 year
February 28, 2019
March 2, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Cure rate
Assess cure rate of PRP and Chemical peeling agents in treatment of Aactive Acne Vulgaris in 3 months duration and compare efficacy of all measures
3 months
Study Arms (3)
PRP
ACTIVE COMPARATORChemical peeling (Salycilic acid)
ACTIVE COMPARATORChemical peeling (Jessenr's solution)
ACTIVE COMPARATORInterventions
Ten mL of venous blood will be drawn in a syringe fill with 1.5 mL of anticoagulant solution (anticoagulant citrate dextrose solution formula A, Baxter, Deerfield, IL). The blood will be centrifuged at 160 g for 10 minutes. After the first spin, the lower red blood cell portion will be discarded, and the supernatant will be centrifuged at 400 g for 10 minutes. The resulting pellet of platelets will be mixed with 1.5 mL of supernatant, which make 1.5 mL of PRP. One mL of 3% calcium chloride will be added to the PRP to induce platelet activation.
SA is a 2-hydroxybenzoic acid (from willow tree) used for superficial peeling due to its strong keratolytic and comedo- lytic properties. It promotes shedding of epidermal cells and due to its lipophilic properties can penetrate comedones and pores to prevent clogging and neutralize bacteria. It promotes desquamation of the upper lipophilic layers of the stratum corneum.19 These chemical properties explain its popularity and success in acne patients.It also has well- documented anti-inflammatory properties.
is a superficial peeling agent used as adjuvant therapy for acne. it is generally proposed to break of the hydrogen bonds of keratin (keratolysis), disruption of cell membranes (cell death) and is bactericidal.
Eligibility Criteria
You may qualify if:
- Patients with active acne vulgaris lesions (inflammatory and non-inflammatory).
- Age range from 14 to 40 years.
- Patients with any topical and systemic treatments will undergo wash out period of one month.
You may not qualify if:
- Patients with herpes labials, or bacterial infection; warts on the face, actinic keratosis, or skin cancer or allergy to medications.
- Systemic retinoids intake in the previous 6 months
- History of keloidal scarring.
- Patients on anticoagulant therapy or aspirin or have a coagulation issue,
- Patients with hemoglobin less than 10g\\dl or platelet less than 105 micron\\l
- Pregnant women
- Immunocompromised patients
- Patients with medical diseases like diabetes mellitus, epilepsy or malignancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
February 28, 2019
First Posted
March 1, 2019
Study Start
January 10, 2020
Primary Completion
January 10, 2021
Study Completion
May 10, 2022
Last Updated
March 5, 2019
Record last verified: 2019-02